Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

LAVAL, QC and VAUGHAN, ON, Jan. 13, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") announced today that, in connection with its previously announced intention to separate its eye health business, its wholly owned subsidiary, Bausch + Lomb Corporation ("Bausch + Lomb"), has publicly filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") and a preliminary base post-receipt pricing procedure ("PREP") prospectus with the securities regulatory authorities in each of the provinces and territories of Canada (other than Quebec) ("Canadian Regulators") relating to a proposed initial public offering ("IPO") of Bausch + Lomb's common shares concurrently in the United States and Canada. All of the shares being offered will be sold by a wholly owned subsidiary of Bausch Health.

Bausch + Lomb Corporation Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering

Bausch Health (BHC) closed the most recent trading day at $27.34, moving -1.51% from the previous trading session.

Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know

Bausch Health Companies, Inc. (BHC) CEO Joe Papa at 40th Annual J.P. Morgan Healthcare Conference (Transcript)

While we do not violate our overall cost basis lightly, we do believe the weakness thus far in 2022 is presenting an opportunity that we want to take advantage.

We're bulking up on this health-care name before it gets away from us

LAVAL, Quebec, Jan. 11, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") will provide a progress update on its business and strategic initiatives in a published presentation designed to complement remarks that will be provided by management at 9 a.m. ET tomorrow, Jan. 12, 2022, during a fireside chat at the 40th Annual J.P.

Bausch Health Will Provide Business And Strategic Update At The 40th Annual J.P. Morgan Healthcare Conference

Bausch has reduced net debt by some $5 billion since the worst of the turmoil in 2017. This makes a dent in leverage, certainly as the underlying business has stabilized.

Bausch Health: Getting Healthier, Gradually

Bausch Health Companies Inc. ( BHC , Financial) has traded in a low range for years, but that could soon change. The company is making progress on its research and recently announced a collaboration with the Glaucoma Research Foundation to raise awareness of hyperemia and how it may have an impact on the lives of patients with glaucoma.

Bausch Health Companies Is Doing Good and Doing Well

Chevron

Honeywell

Eli Lilly

Appearing on CNBC's "Halftime Report," Jim Cramer explained why Chevron, Eli Lilly, Honeywell and Bausch Health are some of his favorite stocks for the new year.

Here are 4 of Jim Cramer's top stock picks for 2022

Our reassessment comes ahead of the company's presentation at the annual J.P. Morgan Healthcare Conference next week.

We're increasing our price target on a club health stock

LAVAL, QC, Jan. 5, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the 40th Annual J.P.

BAUSCH HEALTH TO PARTICIPATE AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Bausch Health (BHC) closed the most recent trading day at $27.79, moving +0.65% from the previous trading session.

Bausch Health (BHC) Outpaces Stock Market Gains: What You Should Know

Data from a Post-Hoc Analysis Supports the Use of Salix's RELISTOR for Patients with Opioid-Induced Constipation and Advanced Illness in the Emergency Department Setting LAVAL, QC, Dec. 22, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) "Bausch Health" and its gastroenterology business, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today announced that The Journal of Emergency Medicine has published a new post-hoc analysis of pooled results on the safety and efficacy of a single dose of RELISTOR® (methylnaltrexone bromide) injection in patients with severe illness and opioid-induced constipation (OIC) who had insufficient response to laxative therapy. Entitled, "First Dose Efficacy of Methylnaltrexone in Patients with Severe Medical Illness and Opioid-Induced Constipation: A Pooled Analysis," the study results demonstrated that an initial dose of RELISTOR injection effectively produced rescue-free laxation (RFL) in greater proportions of severely ill patients with OIC compared to placebo (61.4% within 4 hours vs.

RELISTOR® (METHYLNALTREXONE BROMIDE) DATA IS PUBLISHED IN THE JOURNAL OF EMERGENCY MEDICINE

The Mad Money host announced a new position in Bausch Health amid the spread of the omicron variant. Here's what you should know.

BHC Stock: 9 Things to Know as Jim Cramer Buys Bausch Health

Apple

AbbVie

Amazon

Alphabet

Morgan Stanley

Microsoft

Wells Fargo

There may be a lot of negativity out there. But for the Charitable Trust, we're staying the course and looking for opportunities.

Cramer's Investing Club: Here's a list of stocks you may want on your buying list

We believe a sum of the parts is greater than the whole analysis is a good case for buying shares of Bausch Health.

Cramer's Investing Club: We're starting a new trust position in a health stock

Following a reduction in the third quarter, Glenview Capital Management's Larry Robbins (Trades, Portfolio) disclosed earlier this week he boosted his stake in Bausch Health Companies Inc. ( BHC , Financial) by 9.13%.

Larry Robbins Boosts Bet on Top Holding Bausch Health

LAVAL, QC, Dec. 6, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced JUBLIA® (efinaconazole) Topical Solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, has received the American Podiatric Medical Association (APMA) Seal of Approval. The APMA Seal of Approval is granted to products that promote good foot health and are of significant value when used in a consistently applied program of daily foot care and regular professional treatment.

APMA Grants Seal of Approval for JUBLIA® (efinaconazole) Topical Solution, 10%

Opioid-Induced Constipation Takes the Spotlight on TikTok Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation Initiatives Aim to Spark Greater Awareness for These Conditions LAVAL, QB, Dec. 3, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, today introduced a collection of digital and social activations aimed at helping adult patients with opioid-induced constipation (OIC), irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Launched during Constipation Awareness Month in December, the digital and social activations are designed to help patients with constipation and their caregivers identify symptoms and potential causes of constipation and find appropriate treatment options.

Salix Brings Educational Resources on Constipation Into the Homes of Patients and Caregivers for Constipation Awareness Month

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Why Is Bausch (BHC) Down 15.6% Since Last Earnings Report?

Bausch Health Companies Inc. (BHC) 4th Annual Evercore ISI HealthCONx Virtual Conference (Transcript)

LAVAL, QC and TRENTON, N.J., Nov. 15, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced its exclusive ONE by ONE and Biotrue® Eye Care Recycling programs have recycled a total of 41,358,603 million units, or 248,516 pounds, of used contact lens, eye and lens care materials.

Bausch + Lomb Reports More Than 41 Million Units Of Contact Lens, Eye And Lens Care Materials Recycled Through ONE By ONE And Biotrue® Eye Care Recycling Programs

LAVAL, QC, Nov. 11, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the treatment of gastrointestinal (GI) and liver diseases, today announced two abstracts featuring new data for rifaximin are being presented at The Liver Meeting™ 2021, organized by the American Association for the Study of Liver Diseases (AASLD), which is taking place virtually Nov. 12-15, 2021. Abstracts available to registered attendees on The Liver Meeting Digital Experience include: Bajaj, Jasmohan et al.

Salix Will Share New Rifaximin Data At AASLD's The Liver Meeting™ 2021

Bausch (BHC) beats on earnings but misses on sales in the third quarter. The company reiterates annual revenue guidance.

Bausch's (BHC) Q3 Earnings Beat Estimates, Revenues Miss

Bausch Health Companies Inc (NYSE: BHC) reported Q3 revenues of $2.111 billion, down 1% Y/Y, missing the consensus of $2.66 billion. Excluding the impact of foreign exchange, divestitures & discontinuations, revenue was flat organically.

Why Did Bausch Health Shares Plunge Today?

Bausch Health Companies, Inc. (BHC) CEO Joe Papa on Q3 2021 Results - Earnings Call Transcript

News for Bausch Health Companies Inc Stock (BHC)